About
EarliPoint Health develops an FDA-cleared medical device using eye-tracking technology to provide objective, quantifiable data that aids clinicians in the early diagnosis and assessment of autism spectrum disorder in children aged 16 to 95 months.
Explore EarliPoint Health's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.